New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2014
06:39 EDTVICLVical reports Q1 EPS (4c), consensus (5c)
Reports Q1 revenue $2.4M, consensus $1.60M.
News For VICL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
10:09 EDTVICLVical management to meet with Roth Capital
Subscribe for More Information
April 22, 2015
09:22 EDTVICLOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CalAmp (CAMP), up 12.7%... Angie's List (ANGI), up 17.4%... Broadcom (BRCM), up 6.3%... Owens Corning (OC), up 3.8%... Yum! Brands (YUM), up 3.3%... Dolby Laboratories (DLB), up 3.6%... Infinera (INFN), up 2.4%... AutoNation (AN), up 2.5%... Amgen (AMGN), up 3.1%... Coca-Cola (KO), up 2%. ALSO HIGHER: Procera Networks (PKT) up 10.4% after being acquired by Francisco Partners in deal valued at $240M... Organovo (ONVO), up 19.2% after entering into a collaboration agreement with Merck Sharp and Dohme... Vical (VICL), up 5.8% after being awarded $4M contract to manufacture HIV vaccines for clinical evaluation... CTI BioPharma (CTIC), up 4.9% after announcing that Phase 3 pacritinib data will be highlighted in a late-breaking oral presentation at ASCO meeting. DOWN AFTER EARNINGS: Chipotle Mexican Grill (CMG), down 5.2%... iRobot (IRBT), down 3.6%... Cree (CREE), down 3.5%... United Rentals (URI), down 4%... Super Micro Computer (SMC), down 2.3%... Thermo Fisher (TMO), down 2.6%. ALSO LOWER: Natural Resource Partners (NRP), down 14% after reducing quarterly distribution 75% to 9c per unit... Trinity Industries (TRN), down 3.5% following a Bloomberg report that the Justice Department has initiated a criminal investigation into Trinity guardrails.
06:36 EDTVICLVical awarded $4M contract to manufacture HIV vaccines for clinical evaluation
Subscribe for More Information
April 21, 2015
06:32 EDTVICLVical presents data from Vaxfectin study
Vical announced that Michael McVoy, Professor of Pediatrics at Virginia Commonwealth University, presented data from preclinical studies testing several combinations of Vaxfectin- formulated glycoprotein-B-encoding DNA vaccines for neutralizing antibody responses. Vaxfectin is Vical's novel, proprietary cationic lipid-based adjuvant and is used in CyMVectin, the company's congenital CMV vaccine candidate. The studies found that vaccines encoding gB provided both fibroblast and epithelial entry neutralizing titers that were comparable to those observed in sera from humans with naturally-acquired CMV infections. The data suggest that CyMVectin has the potential to induce neutralizing antibodies against a broad range of cells.
April 20, 2015
07:06 EDTVICLVical management to meet with Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use